Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.
Divisions of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
Diabetes Obes Metab. 2019 Jun;21(6):1498-1501. doi: 10.1111/dom.13672. Epub 2019 Mar 25.
In this study we prospectively collected data on the use of liraglutide 3 mg in obese Arab patients. As part of routine care, 2092 patients were dispensed liraglutide 3 mg. Median age was 38 years and 77% were women. Median baseline weight was 95 kg and body mass index was 36.6 kg/m . Of the patients, 188 (9%) had previous bariatric surgery. Seven hundred and eighty-seven patients were treated for ≥16 weeks and their median (interquartile range) weight loss was 6.0 (2.4-9.4) kg, equivalent to 6.4% (2.6%-9.7%) of baseline weight (P < 0.0001, n = 787). Of those treated for ≥16 weeks, 474 (60%) achieved a weight loss of >5% of baseline weight while 182 (23%) achieved >10% weight loss. There was no difference in percentage weight loss between postbariatric surgery (n = 76) and non-surgical patients (n = 711). As a result of adverse events, mainly gastrointestinal symptoms, 140 (6.7%) of the patients stopped treatment. One patient developed acute pancreatitis in the context of gallstone disease but made an uneventful recovery. Liraglutide 3 mg was well tolerated and resulted in weight loss in routine clinical care similar to that seen in randomized controlled trials.
在这项研究中，我们前瞻性地收集了肥胖阿拉伯患者使用利拉鲁肽 3 毫克的数据。作为常规护理的一部分，2092 名患者被配给利拉鲁肽 3 毫克。中位年龄为 38 岁，77%为女性。中位基线体重为 95 公斤，体重指数为 36.6 公斤/平方米。其中 188 名（9%）患者有既往减重手术史。787 名患者接受了≥16 周的治疗，他们的中位（四分位间距）体重减轻为 6.0（2.4-9.4）公斤，相当于基线体重的 6.4%（2.6%-9.7%）（P<0.0001，n=787）。在接受≥16 周治疗的患者中，474 名（60%）患者的体重减轻>基线体重的 5%，而 182 名（23%）患者的体重减轻>10%。减重手术后（n=76）和非手术患者（n=711）的体重减轻百分比无差异。由于不良事件，主要是胃肠道症状，140 名（6.7%）患者停止治疗。一名患者在胆石病的背景下发生急性胰腺炎，但恢复顺利。利拉鲁肽 3 毫克耐受性良好，导致体重减轻，在常规临床护理中与随机对照试验中观察到的结果相似。
